Kortenbach Karen-Cecilie, Løgager Vibeke, Thomsen Henrik S, Boesen Lars
Department of Radiology, Herlev Gentofte University Hospital, Herlev, Denmark.
Department of Urological Research, Herlev Gentofte University Hospital, Herlev, Denmark.
Acta Radiol Open. 2022 Apr 20;11(4):20584601221094825. doi: 10.1177/20584601221094825. eCollection 2022 Apr.
Only limited data have been published on the diagnostic accuracy of combining biparametric (bp) magnetic resonance imaging (MRI) and prostate-specific antigen density (PSAd) to rule out biopsies.
The purpose is to assess the 2-year risk of being diagnosed with sPCa following the strategy of avoiding immediate biopsies in men with non-suspicious bp MRIs and a PSAd <0.15 ng/mL.
Two hundred biopsy-naïve men with clinical suspicion of PCa underwent a pre-biopsy bp MRI from March to July 2019. Of these, 109 men had a Prostate Imaging Reporting and Data System (PI-RADS) score of 1-3 including 77 men with calculated PSAd <0.15 ng/mL. As a result, no biopsies were performed in these 77 men, who were clinically followed up for at least 2 years and re-examined in case of rising suspicion of sPCa. The remaining 32 men with a calculated PSAd ≥0.15 ng/mL underwent systematic biopsies and targeted biopsies of any PI-RADS 3 lesion.
One of the 77 men (1.3%) had an sPCa diagnosed within 2 years of follow-up. All men were referred back to their general practitioner within 1 year and 9% (7/77) were re-referred to the urology department during follow-up. Among these men, 43% (3/7) continued to have PSA levels that were above their individual thresholds at confirmatory testing and underwent secondary MRI scans.
No biopsies for men with bpMRI results exhibiting maximum PI-RADS 3 and with a PSAd <0.15 ng/mL resulted in a 2-year risk of being diagnosed with sPCa of 1.3%.
关于双参数(bp)磁共振成像(MRI)与前列腺特异性抗原密度(PSAd)联合使用以排除活检的诊断准确性,仅有有限的数据发表。
旨在评估对于bp MRI无可疑表现且PSAd<0.15 ng/mL的男性,采用避免立即活检策略后2年被诊断为临床有意义前列腺癌(sPCa)的风险。
2019年3月至7月,200名临床上怀疑患有前列腺癌且未接受过活检的男性进行了活检前bp MRI检查。其中,109名男性的前列腺影像报告和数据系统(PI-RADS)评分为1-3分,包括77名计算得出的PSAd<0.15 ng/mL的男性。结果,这77名男性未进行活检,对其进行了至少2年的临床随访,若怀疑发生sPCa则重新检查。其余32名计算得出的PSAd≥0.15 ng/mL的男性接受了系统活检以及对任何PI-RADS 3级病变的靶向活检。
77名男性中有1名(1.3%)在随访的2年内被诊断为sPCa。所有男性在1年内均被转回其全科医生处,随访期间9%(7/77)的男性被再次转诊至泌尿外科。在这些男性中,43%(3/7)在确诊检查时PSA水平仍高于其个体阈值,并接受了二次MRI扫描。
对于bp MRI结果显示最高PI-RADS 3级且PSAd<0.15 ng/mL的男性不进行活检,其2年被诊断为sPCa的风险为1.3%。